Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.
AffiliationDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, Withington, Manchester, England.
MetadataShow full item record
AbstractInterleukin-2 has demonstrated significant and consistent activity against melanoma even in patients who have been treated previously with other modalities. This paper reviews local treatment, systemic treatment with single-agent, combination, and high-dose chemotherapy, and new agents; biologic modifier therapy, including tumor vaccines and active specific immunization, and interferons; and recombinant interleukin-2, which has activity when used alone, with lymphokine-activated killer cells, chemotherapy, or biologic modifiers. Tumor response, predictors of response, and survival are also discussed.
CitationRecombinant interleukin-2 and other types of treatment of advanced malignant melanoma. 1991, 3 (2):364-76 Curr Opin Oncol
JournalCurrent Opinion in Oncology
- Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
- Authors: Garbe C
- Issue date: 1993 Aug
- Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
- Authors: Legha SS, Buzaid AC
- Issue date: 1993 Dec
- Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
- Authors: Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG
- Issue date: 1992 Jun 17
- Treatment of malignant melanoma with interleukin-2.
- Authors: Philip PA, Flaherty L
- Issue date: 1997 Feb
- Systemic therapy in disseminated melanoma.
- Authors: Rümke PH
- Issue date: 1992 Nov-Dec